The FDA standardized bioequivalence administration protocols across product-specific guidances for generic chewable oral solid dosage forms to better align with harmonized international testing standards. The move addresses variation in how chewable bioequivalence studies are administered, aiming to reduce methodological differences that can complicate cross-study comparisons and regulatory review.